Colorectal Cancer Drugs Market

SKU: DMPH4089 | Last Updated On: Oct 13 2022 | Available Formats

>Colorectal Cancer Drugs Market Expected to reach a high CAGR of 6.5% By 2029:

Colorectal Cancer Drugs Market is segmented By Type(Vascular endothelial growth factor inhibitors, Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors, Tyrosine Kinase (TKI) Inhibitors, Immunomodulators, and BRAF or MEK Inhibitors), By Therapy(Immunotherapy, Targeted Therapy, and Chemotherapy), By Distribution channels(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029.

Colorectal Cancer Drugs Market is estimated to reach at a CAGR of 3.4% during the forecast period (2022-2029).

Colon cancer is also called colorectal cancer, is a term that combines colon cancer and rectal cancer, which begins in the rectum. Colon cancer is a type of cancer that starts in the large intestine (colon), is the final part of the digestive tract. It mainly affects older adults, though it can happen at any age, usually begins as tiny, non-cancerous (benign) clumps of cells called polyps that form inside the colon. As time passes, some of these polyps can become colon cancers. They may be small and produce few if any, symptoms. Usually, doctors recommend regular screening tests to prevent colon cancer by identifying and removing polyps before they turn into cancer. Signs and symptoms associated with colorectal cancer are weight loss, fatigue, weakness, abdominal discomfort, pain, cramps, persistent change in bowel habits, diarrhea and constipation, rectal bleeding, and blood in the stools and others.

Many treatments are available to control it if colon cancer develops, including surgery, radiation therapy, and drug treatments, such as chemotherapy, targeted therapy, and immunotherapy.

Colorectal Cancer Drugs Market Scope



Market CAGR


Segments Covered

By Type, By Therapy, By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To know more insights into the Market, Get Our Sample Brochure

Colorectal Cancer Drugs Market Dynamics

The global Colorectal Cancer Drug market growth is driven by the growing incidence of Colorectal cancers, and changing  lifestyle, increasing geriatric population, increasing awareness, government policies to provide better care for colorectal cancer.

Increasing incidence of Colorectal Cancers, is expected to drive the global Colorectal Cancer Drug market during the forecast period.

The number of colorectal cancer cases worldwide has been increasing. As per the American Cancer Society (ACS) estimates, there will be around 101,420 new colon cancer cases, and around 44,180 new cases of rectal cancer are registered in the USA in 2019. The diagnosed incident colorectal cancer cases are expected to increase by 27.3% to 672,400 cases by 2037. This increase can be attributed to a low-fiber diet, obesity, alcohol and tobacco consumption, amongst others. The increase in the number of colorectal cases will add to the overall global colorectal cancer drug market.

Increased Awareness and Effective Product Launches is expected to drive the global Colorectal Cancer Drug market during the forecast period.

Increased awareness about colorectal cancer and rise in product launch driving the global colorectal drug market rapidly.

Many market key leaders have introduced several advanced medicines for effective colorectal cancer treatment. For instance, In July 2019, Amgen and Allergan launched Mvasi and Kanjinti, the first Anticancer Biosimilars in the US used to treat colorectal cancer.

Increased usage of biologics and targeted therapies is likely to hamper the global colorectal cancer drugs market.

Increased usage of biologics and targeted therapies is likely to hamper the market growth. Biologic therapy helps the body’s immune system fight against cancer rather than chemical drugs, which reduces the body’s immune power. Targeted therapies block the growth and spreading of colorectal cancer even in stage IV, where chemical drugs are ineffective. For instance, the FDA has approved some targeted therapies to treat colorectal cancer, including bevacizumab, cetuximab, and panitumumab. The advantages of biologics drugs and targeted therapies over conventional chemical drugs might negatively influence the market.

COVID-19 Impact Analysis

Due to the covid-19 pandemic outbreak, the market for Global Colorectal Cancer drugs market was seen to be down, due to the barriers in production and sales segments. Since the outbreak led to the shutdown of all manufacturing firms except for masks, sanitizers and ventilators. Hence, the Drugs were manufactured less compared to previous years, during the outbreak.

Segment Analysis

Based on the Type, the global Colorectal cancer drugs market is segmented into Vascular endothelial growth factor inhibitors (VEGF), Epidermal growth factor receptor (EGFR) inhibitors, Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors, BRAF or MEK Inhibitors, Tyrosine Kinase (TKI) Inhibitors, Immunomodulators.

Vascular endothelial growth factor inhibitors are expected have largest share. The Vascular endothelial growth factor (VEGF)/ vascular endothelial growth factor receptor (VEGFR) inhibitors are the agents that inhibit VEGF and VEGFR. VEGR and VEGFR (a tyrosine kinase receptor) signaling modulate angiogenesis, making new blood vessels from existing blood vessels. They are used to treat various types of cancers. The drugs included in this type Avastin, Eylea, cometriq. The Avastin segment, picked up $7.12 billion of global annual sales by 2019. For instance,

Based on the Therapy Type, the global Colorectal Cancer Drugs market is segmented into Immunotherapy, Target therapy, Chemotherapy.

Immunotherapy is used to fight cancer cells by taking advantage of the human immune system. There are several immunotherapy drugs available for colorectal cancer worldwide. They are targeted antibodies and checkpoint inhibitors. Furthermore, growing R&D on combination therapy is increasing the immunotherapy segment. For instance, In August 2018, United States Food and Drug Administration approved a combination of immunotherapeutic drugs ipilimumab (Yervoy), and nivolumab (Opdivo) to treat metastatic colorectal cancer have been treated previously with standard chemotherapy drugs. Moreover, the expansion of therapeutic applications of immunotherapeutic agents to colorectal cancer further increases the market growth.

Based on Distribution channel, the hospital pharmacy are expected to dominate the Global Colorectal Cancer Drugs market during the forecast period

The hospital pharmacies held the largest share in the global colorectal cancer drugs market. This is mainly owing to increasing number of patients suffering from conditions which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment.Also the medications can only be administrated by intravenously under supervision of medical practioners at these locations.

Colorectal Cancer Drugs Market Geographical Analysis:

North America served the largest share of the market due to the increasing prevalence of urological cancer diseases. According to the American Cancer Society’s estimates for the number of colorectal cancer cases in the United States for 2021 are: 104,270 new cases of colon cancer, 45,230 new cases of rectal cancer. The existence of a highly developed healthcare system, the high degree of acceptance by medical practitioners of novel chemotherapy and immunotherapy methods, the total availability of advanced technological tools, FDA approval of new drugs and many companies are developing oncology products.

The Asia Pacific is expected to be the fastest-growing market over the forecast period owing to increasing prevalence rate, increasing focus on preventive care, and government initiatives promoting technological innovations. For instance, Chi-Med's Fruquintinob has got approved for the treatment of colorectal cancer in China. This is expected to increase access to colorectal cancer therapeutics in China.

Colorectal Cancer Drugs Market Competitive Landscape:

The Global Colorectal Cancer Drugs Market is quite competitive with some key competitors like Genentech, Pfizer, Roche, Sanofi, Bristol-Myers Squibb, Amgen, Merck & Co, Teva Pharmaceuticals, Eli Lilly and Company, Abbott Laboratories. The key players are adopting various growth strategies such as product launch, acquisitions and investments in multiple sectors. For instance, In July 2019 – Pfizer, a key player in the market for colorectal cancer medications, completed the acquisition of Array BioPharma Inc. for strengthening the oncology pipeline for colorectal cancer treatment.

Roche Inc.

Roche was founded in 1896 in Basel, Switzerland. It creates innovative medicines and diagnostic tests that help millions of patients globally. Roche was one of the first companies to bring targeted treatments to patients. With our combined strength in pharmaceuticals and diagnostics, we are better equipped than any other company to drive personalized healthcare further. Two-thirds of our Research and Development projects are being developed with companion diagnostics.

Product Portfolio: The company portfolio includes Oncology, Neurology, Endocrinology, Infectious diseases and others.

Key developments:





Colorectal Cancer

Drug: Bevacizumab

Drug: Capecitabine

Phase 3

Hoffmann-La Roche

Frequently Asked Questions

What is the Projected CAGR value of the Colorectal Cancer Drugs Market?

Colorectal Cancer Drugs Market is expected to grow at a CAGR of 6.5% during the forecasting period 2022-2029.

Which region controlled the global market during 2022-2029?

North America region Controls the Colorectal Cancer Drugs Market during 2022-2029

Which is the fastest growing region in the Colorectal Cancer Drugs Market?

Among all regions, Asia Pacific is the fastest growing market share during the forecast period.

Trending Topics

Pet Food Market

Organic Pet Food Market

Freeze-Dried Pet Food Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!